Related Experiment Video
Updated: Jul 17, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Transient abnormal myelopoiesis in a premature infant with Down syndrome: A case report
Jin Wang1, Dan Wang, Xuwei Tao
1Department of Neonatology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei Province, China.
Insights
Transient abnormal myelopoiesis (TAM) in premature infants with GATA1 mutations can resolve faster than in term infants. Early diagnosis and monitoring are crucial for managing this condition and preventing potential complications like myeloid leukemia.
Area of Science:
- Hematology
- Genetics
- Neonatology
Background:
- Transient abnormal myelopoiesis (TAM) is a condition often associated with GATA1 gene mutations.
- While typically self-alleviating in term infants around 3-4 months postpartum, its course in premature infants is less understood.
- This case highlights an earlier remission in a premature infant.
Purpose of the Study:
- To report on the clinical course and genetic findings of transient abnormal myelopoiesis in a premature infant.
- To compare the remission timeline with that typically observed in term infants.
- To emphasize the importance of ongoing surveillance for potential complications.
Main Methods:
- Diagnosis involved bone marrow cytology, whole-exon gene detection, and FISH analysis.
- The infant received supportive care including anti-infection, liver protection, hydration, and alkalization for leukocytosis.
- Genetic mutation status was monitored post-diagnosis.
Main Results:
- A premature infant diagnosed with TAM and a GATA1 mutation achieved GATA1 negativity within one month.
- This remission occurred earlier than the typical 3-4 month self-alleviation period in term infants.
- Supportive treatments were administered for leukocytosis.
Conclusions:
- Transient abnormal myelopoiesis in premature infants may resolve more rapidly than in term infants.
- Distinguishing TAM from congenital leukemia is critical.
- Continuous follow-up is essential due to the potential risk of developing myeloid leukemia, particularly in Down syndrome patients.
Rationale:
Transient abnormal myelopoiesis with mutations in GATA1 gene can be self-alleviated after 3 to 4 months of birth in term infant, however, the premature infant with this disease in our research achieved remission earlier.
Patient Concerns:
A 10-hours-old girl was diagnosed with transient abnormal myelopoiesis with GATA1 mutation.
Diagnosis:
Transient abnormal myelopoiesis in a premature infant was suspected.
Interventions:
The patient received anti-infection, liver protection, hydration, and alkalization treatments for leukocytosis.
Outcomes:
After admission, the infant was diagnosed with TAM with GATA1 mutation after completing bone marrow cytology, whole-exon gene detection, and FISH detection. The GATA1 gene mutation of this baby turns negative a month later.
Lessons:
Transient abnormal myelopoiesis differs from congenital leukemia. Most children can self-alleviate after 3 to 4 months of birth, and GATA1 mutation turns negative. Since some children with transient abnormal myelopoiesis may develop myeloid leukemia of Down syndrome, continuous follow-up is required once transient abnormal myelopoiesis is diagnosed for early detection and treatment.
Related Concept Videos
01:49Meiosis I
02:57Meiosis vs. Mitosis
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
01:15Differentiation of Common Myeloid Progenitor Cells